Inhibition of microRNA (miRNA)-21 could represent a therapeutic strategy for the treatment of chronic kidney diseases, including Alport nephropathy, say the researchers of a new study. Gomez et al. assessed the therapeutic potential of highly specific oligonucleotides that distribute to the kidney and inhibit miRNA function following subcutaneous administration. Injection of these oligonucleotides into mice with Alport nephropathy resulted in milder kidney disease, improved survival and reduced glomerulosclerosis, interstitial fibrosis and inflammation.
References
Gomez, I. G. et al. Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways. J. Clin. Invest. 10.1172/JCI75852
Rights and permissions
About this article
Cite this article
MicroRNA inhibition in Alport syndrome. Nat Rev Nephrol 11, 64 (2015). https://doi.org/10.1038/nrneph.2014.234
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2014.234